Table 2. Comparison of Pretreatment... | American Society of Hematology

Table 2.

Comparison of Pretreatment Clinical and Hematologic Characteristics of the Patients With t(9; 11) and t(11q23)

Characteristic	t(9; 11)	t(11q23)^*	P
	(n = 24)	(n = 23)
Sex (% females)	63	48	.39
Age (median, yr)	44	39	.76
FAB (%)			.02
M1	0	13
M2	4	4
M4	8	30	.07^†
M5	83	43	.006^†
AML^‡	4	9
Hemoglobin (median, g/dL)	10.2	9.6	.94
Platelets (median, ×10⁹/L)	48.5	49.0	.86
WBC (median, ×10⁹/L)	9.4	29.7	.23
% Blood blasts (median)	47	64	.17
% Bone marrow blasts (median)	90	88	.21
Auer rods (% positive)	13	26	.29
MDFρ (no. positive/no. evaluated)
Erythroid	0/13	0/17	1.0
Megakaryocytic	2/5	1/6	.55
Granulocytic	3/10	4/12	1.0
Organ involvement (% positive)
Skin	4	14	.34
Gum hypertrophy	21	36	.33
Splenomegaly	8	5	1.0
Hepatomegaly	21	9	.42
Lymphadenopathy	17	18	1.0

Characteristic	t(9; 11)	t(11q23)^*	P
	(n = 24)	(n = 23)
Sex (% females)	63	48	.39
Age (median, yr)	44	39	.76
FAB (%)			.02
M1	0	13
M2	4	4
M4	8	30	.07^†
M5	83	43	.006^†
AML^‡	4	9
Hemoglobin (median, g/dL)	10.2	9.6	.94
Platelets (median, ×10⁹/L)	48.5	49.0	.86
WBC (median, ×10⁹/L)	9.4	29.7	.23
% Blood blasts (median)	47	64	.17
% Bone marrow blasts (median)	90	88	.21
Auer rods (% positive)	13	26	.29
MDFρ (no. positive/no. evaluated)
Erythroid	0/13	0/17	1.0
Megakaryocytic	2/5	1/6	.55
Granulocytic	3/10	4/12	1.0
Organ involvement (% positive)
Skin	4	14	.34
Gum hypertrophy	21	36	.33
Splenomegaly	8	5	1.0
Hepatomegaly	21	9	.42
Lymphadenopathy	17	18	1.0

t(11q23), translocations involving the band 11q23 other than t(9; 11).

Based on multiple comparisons with the level of significance adjusted to .01.

AML, acute undifferentiated leukemia or acute myeloid, FAB unclassifiable leukemia on central review.

ρ MDF, myelodysplastic features.